" /> " />

Teva Pharma Earnings Estimate

TEVA Stock  USD 14.11  0.32  2.22%   
The next projected EPS of Teva Pharma is estimated to be 0.58 with future projections ranging from a low of 0.54 to a high of 0.61. Teva Pharma's most recent 12-month trailing earnings per share (EPS TTM) is at -0.5. Please be aware that the consensus of earnings estimates for Teva Pharma Industries is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Teva Pharma is projected to generate 0.58 in earnings per share on the 30th of June 2024. Teva Pharma earnings estimates module stress-tests analyst consensus about projected Teva Pharma Industries EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Teva Pharma, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Teva Pharma's earnings estimates, investors can diagnose different trends across Teva Pharma's analyst sentiment over time as well as compare current estimates against different timeframes. As of March 29, 2024, Gross Profit is expected to decline to about 4.8 B. The current year's Pretax Profit Margin is expected to grow to -0.04
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Teva Pharma Earnings Estimation Breakdown

The calculation of Teva Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Teva Pharma is estimated to be 0.58 with the future projection ranging from a low of 0.54 to a high of 0.61. Please be aware that this consensus of annual earnings estimates for Teva Pharma Industries is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
0.54
Lowest
Expected EPS
0.58
0.61
Highest

Teva Pharma Earnings Projection Consensus

Suppose the current estimates of Teva Pharma's value are higher than the current market price of the Teva Pharma stock. In this case, investors may conclude that Teva Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Teva Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2024Current EPS (TTM)
2682.16%
0.0
0.58
-0.5

Teva Pharma Earnings History

Earnings estimate consensus by Teva Pharma Industries analysts from Wall Street is used by the market to judge Teva Pharma's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Teva Pharma's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Teva Pharma Quarterly Gross Profit

2.42 Billion

The current year's Price Earnings To Growth Ratio is expected to grow to 0.33, whereas Retained Earnings are projected to grow to (12.9 B). As of March 29, 2024, Common Stock Shares Outstanding is expected to decline to about 777 M. The current year's Net Loss is expected to grow to about (2 B).
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Teva Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
12.3314.1115.89
Details
Intrinsic
Valuation
LowRealHigh
13.9515.7317.51
Details
Naive
Forecast
LowNextHigh
12.8714.6516.43
Details
13 Analysts
Consensus
LowTargetHigh
9.6110.5611.72
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Teva Pharma. Your research has to be compared to or analyzed against Teva Pharma's peers to derive any actionable benefits. When done correctly, Teva Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Teva Pharma Industries. Note that many institutional investors and large investment bankers can move markets due to the volume of Teva assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Teva Pharma. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Teva Pharma's stock price in the short term.

Teva Pharma Earnings per Share Projection vs Actual

Actual Earning per Share of Teva Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Teva Pharma Industries predict the company's earnings will be in the future. The higher the earnings per share of Teva Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Teva Pharma Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Teva Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Teva Pharma should always be considered in relation to other companies to make a more educated investment decision.

Teva Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Teva Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2024-01-31
2023-12-310.771.00.2329 
2023-11-08
2023-09-300.610.6-0.01
2023-08-02
2023-06-300.530.560.03
2023-05-10
2023-03-310.560.4-0.1628 
2023-02-08
2022-12-310.710.710.0
2022-11-03
2022-09-300.620.59-0.03
2022-07-26
2022-06-300.560.680.1221 
2022-05-03
2022-03-310.560.55-0.01
2022-02-09
2021-12-310.730.770.04
2021-10-27
2021-09-300.650.59-0.06
2021-07-28
2021-06-300.590.590.0
2021-04-28
2021-03-310.590.630.04
2021-02-10
2020-12-310.630.680.05
2020-11-05
2020-09-300.580.580.0
2020-08-05
2020-06-300.530.550.02
2020-05-07
2020-03-310.590.760.1728 
2020-02-12
2019-12-310.610.620.01
2019-11-07
2019-09-300.590.58-0.01
2019-08-07
2019-06-300.570.60.03
2019-05-03
2019-03-310.580.60.02
2019-02-13
2018-12-310.540.53-0.01
2018-11-01
2018-09-300.540.680.1425 
2018-08-02
2018-06-300.640.780.1421 
2018-05-03
2018-03-310.670.940.2740 
2018-02-08
2017-12-310.760.930.1722 
2017-11-02
2017-09-301.041.0-0.04
2017-08-03
2017-06-301.061.02-0.04
2017-05-11
2017-03-311.031.060.03
2017-02-13
2016-12-311.351.380.03
2016-11-15
2016-09-301.281.310.03
2016-08-04
2016-06-301.21.250.05
2016-05-09
2016-03-311.171.20.03
2016-02-11
2015-12-311.291.28-0.01
2015-10-29
2015-09-301.281.350.07
2015-07-27
2015-06-301.311.430.12
2015-04-30
2015-03-311.251.360.11
2015-02-05
2014-12-311.311.310.0
2014-10-30
2014-09-301.241.320.08
2014-07-31
2014-06-301.221.230.01
2014-05-01
2014-03-311.211.220.01
2014-02-06
2013-12-311.41.420.02
2013-10-31
2013-09-301.261.270.01
2013-08-01
2013-06-301.21.20.0
2013-05-02
2013-03-311.11.120.02
2013-02-07
2012-12-311.331.32-0.01
2012-11-01
2012-09-301.251.280.03
2012-08-02
2012-06-301.281.280.0
2012-05-08
2012-03-311.441.470.03
2012-02-15
2011-12-311.581.590.01
2011-11-02
2011-09-301.221.250.03
2011-07-27
2011-06-301.081.10.02
2011-05-11
2011-03-311.031.040.01
2011-02-08
2010-12-311.291.25-0.04
2010-11-02
2010-09-301.261.30.04
2010-07-27
2010-06-301.031.080.05
2010-05-04
2010-03-310.890.910.02
2010-02-16
2009-12-310.950.94-0.01
2009-11-03
2009-09-300.880.890.01
2009-07-28
2009-06-300.80.830.03
2009-05-05
2009-03-310.680.710.03
2009-02-17
2008-12-310.730.760.03
2008-11-06
2008-09-300.70.720.02
2008-07-29
2008-06-300.640.680.04
2008-05-06
2008-03-310.630.70.0711 
2008-02-12
2007-12-310.660.690.03
2007-10-30
2007-09-300.630.640.01
2007-07-31
2007-06-300.560.630.0712 
2007-05-02
2007-03-310.390.420.03
2007-02-12
2006-12-310.580.53-0.05
2006-11-07
2006-09-300.630.740.1117 
2006-08-07
2006-06-300.460.660.243 
2006-05-10
2006-03-310.410.37-0.04
2006-02-28
2005-12-310.430.450.02
2005-11-08
2005-09-300.380.40.02
2005-08-01
2005-06-300.360.360.0
2005-05-03
2005-03-310.380.380.0
2005-02-15
2004-12-310.390.410.02
2004-11-04
2004-09-300.350.380.03
2004-08-03
2004-06-300.330.350.02
2004-05-04
2004-03-310.290.320.0310 
2004-02-17
2003-12-310.280.310.0310 
2003-11-03
2003-09-300.240.270.0312 
2003-07-29
2003-06-300.220.250.0313 
2003-05-01
2003-03-310.230.250.02
2003-02-18
2002-12-310.230.250.02
2002-10-29
2002-09-300.170.180.01
2002-07-29
2002-06-300.160.170.01
2002-04-29
2002-03-310.140.160.0214 
2002-02-14
2001-12-310.150.170.0213 
2001-10-31
2001-09-300.130.140.01
2001-07-26
2001-06-300.110.120.01
2001-04-24
2001-03-310.090.10.0111 
2000-11-07
2000-09-300.090.090.0
2000-07-31
2000-06-300.080.080.0
2000-05-04
2000-03-310.070.080.0114 
2000-02-11
1999-12-310.150.08-0.0746 
1999-11-01
1999-09-300.070.070.0
1999-07-29
1999-06-300.060.060.0
1999-05-06
1999-03-310.060.060.0
1998-11-10
1998-09-300.050.050.0
1998-08-07
1998-06-300.040.040.0
1998-05-11
1998-03-310.060.05-0.0116 
1998-02-24
1997-12-310.050.04-0.0120 
1997-11-11
1997-09-300.070.070.0
1997-08-04
1997-06-300.070.070.0
1997-05-08
1997-03-310.060.060.0
1997-02-24
1996-12-310.060.060.0
1996-11-11
1996-09-300.040.050.0125 
1996-08-15
1996-06-300.050.03-0.0240 
1996-05-13
1996-03-310.050.050.0
1996-02-29
1995-12-310.050.050.0
1995-11-07
1995-09-300.050.050.0
1995-08-06
1995-06-300.050.050.0

About Teva Pharma Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Teva Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Teva Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Teva Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings-13.5 B-12.9 B
Retained Earnings Total Equity-9.5 B-9.9 B
Price Earnings Ratio(20.90)(19.85)
Price Earnings To Growth Ratio 0.27  0.33 

Teva Pharma Investors Sentiment

The influence of Teva Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Teva. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Teva Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Teva Pharma.

Teva Pharma Implied Volatility

    
  30.4  
Teva Pharma's implied volatility exposes the market's sentiment of Teva Pharma Industries stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Teva Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Teva Pharma stock will not fluctuate a lot when Teva Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharma's short interest history, or implied volatility extrapolated from Teva Pharma options trading.

Currently Active Assets on Macroaxis

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Teva Stock analysis

When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Directory
Find actively traded commodities issued by global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.50)
Revenue Per Share
14.161
Quarterly Revenue Growth
0.148
Return On Assets
0.0454
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.